Status
Conditions
Treatments
About
Assessment of feasibility, safety and outcomes of transcatheter valve interventions
Full description
Transcatheter valve therapies have a growing impact on daily medical practice since the first human percutaneous implantation of an aortic valve bioprosthesis by A. Cribier in 2002. While initially these techniques were reserved for patients at prohibitive risk for surgical aortic valve implantation, indications moving toward patients at high and intermediate risk.
Outcomes of these percutaneous interventions need to be monitored to assess quality of care and tailor indications in this rapidly moving field in interventional cardiology.
Trial objectives and Design Trial objectives
Secondary endpoints The secondary endpoints of the study are hemodynamic outcomes after transcatheter valve interventions according to the Valve Academic Research Consortium criteria (2-3). Quality of life parameters, as well as exercise tolerance will be assessed.
Trial Design The design of the trial is a prospective non-interventional registry.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
5,000 participants in 3 patient groups
Loading...
Central trial contact
Marina Claes; Christophe Dubois, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal